127 related articles for article (PubMed ID: 38477916)
1. Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer.
Berg T; Jensen MB; Rossing M; Bechmann T; Donskov F; Knoop AS; Ejlertsen B
JAMA Netw Open; 2024 Mar; 7(3):e242174. PubMed ID: 38477916
[TBL] [Abstract][Full Text] [Related]
2. Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
Plichta JK; Thomas SM; Hayes DF; Chavez-MacGregor M; Allison K; de Los Santos J; Fowler AM; Giuliano AE; Sharma P; Smith BD; van Eycken E; Edge SB; Hortobagyi GN
J Clin Oncol; 2023 May; 41(14):2546-2560. PubMed ID: 36944149
[TBL] [Abstract][Full Text] [Related]
3. A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.
Plichta JK; Thomas SM; Sergesketter AR; Greenup RA; Rosenberger LH; Fayanju OM; Kimmick G; Force J; Hyslop T; Hwang ES
Ann Surg; 2022 Apr; 275(4):784-792. PubMed ID: 32657941
[TBL] [Abstract][Full Text] [Related]
4. An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.
Chan SK; O'Sullivan B; Huang SH; Chau TC; Lam KO; Chan SY; Tong CC; Vardhanabhuti V; Kwong DL; Ng CY; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454830
[TBL] [Abstract][Full Text] [Related]
5. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.
Husain ZA; Chen T; Corso CD; Wang Z; Park H; Judson B; Yarbrough W; Deshpande H; Mehra S; Kuo P; Decker RH; Burtness BA
JAMA Oncol; 2017 Mar; 3(3):358-365. PubMed ID: 27737449
[TBL] [Abstract][Full Text] [Related]
7. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
8. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.
O'Sullivan B; Huang SH; Su J; Garden AS; Sturgis EM; Dahlstrom K; Lee N; Riaz N; Pei X; Koyfman SA; Adelstein D; Burkey BB; Friborg J; Kristensen CA; Gothelf AB; Hoebers F; Kremer B; Speel EJ; Bowles DW; Raben D; Karam SD; Yu E; Xu W
Lancet Oncol; 2016 Apr; 17(4):440-451. PubMed ID: 26936027
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
11. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
[TBL] [Abstract][Full Text] [Related]
12. A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study.
Zhao J; Bian S; Di X; Xiao C
Curr Oncol; 2023 Dec; 31(1):115-131. PubMed ID: 38248093
[TBL] [Abstract][Full Text] [Related]
13. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D
Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042
[TBL] [Abstract][Full Text] [Related]
14. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
16. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.
Weiss A; Chavez-MacGregor M; Lichtensztajn DY; Yi M; Tadros A; Hortobagyi GN; Giordano SH; Hunt KK; Mittendorf EA
JAMA Oncol; 2018 Feb; 4(2):203-209. PubMed ID: 29222540
[TBL] [Abstract][Full Text] [Related]
17. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
18. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
19. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.
Xu L; Li JH; Ye JM; Duan XN; Cheng YJ; Xin L; Liu Q; Zhou B; Liu YH
Chin Med J (Engl); 2017 Aug; 130(16):1945-1952. PubMed ID: 28776547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
